Jeil Pharmaceutical Co. Ltd. has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, ulcerative colitis, rheumatoid arthritis, autoimmune disease, cardiovascular disorders and dermatological and inflammatory disorders and neurological disorders, among others.